Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 7/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.30 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.30 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
| ▸ | AOC1 | P19801 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30107439 | 0.85 | LPL (0.40) | F11LPLLIPGUCHL1AOC1 | |
| SCHEMBL20517178 | 0.85 | LPL (0.40) | F11LPLLIPGUCHL1AOC1 | |
| SCHEMBL23295525 | 0.81 | CYP11B1 (0.38) | F11LPLLIPGUCHL1CYP11B1 | |
| SCHEMBL29542703 | 0.81 | CYP11B1 (0.38) | F11LPLLIPGUCHL1CYP11B1 | |
| SCHEMBL28990805 | 0.78 | F11 (0.34) | F11LPLLIPGUCHL1FFAR1 | |
| SCHEMBL30737822 | 0.76 | LPL (0.42) | F11LPLLIPGCXCR2 | |
| SCHEMBL15810486 | 0.76 | LPL (0.42) | F11LPLLIPGCXCR2 | |
| SCHEMBL2352761 | 0.76 | LPL (0.34) | F11LPLLIPGUCHL1FFAR1 | |
| SCHEMBL29515710 | 0.76 | LPL (0.34) | F11LPLLIPGUCHL1FFAR1 | |
| SCHEMBL12475203 | 0.75 | LIPG (0.40) | F11LPLLIPGUCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170002016-A1 | AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS | TRPM8, TRPM7, TRPM5 | F11 4636/4885LPL 4036/4885LIPG 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.